跳转至内容
Merck
CN

K2628

酮替芬 富马酸盐

≥99% (TLC), powder, H₁ histamine receptor antagonist

登录 查看组织和合同定价。

选择尺寸

变更视图

关于此项目

经验公式(希尔记法):
C19H19NOS · C4H4O4
化学文摘社编号:
分子量:
425.50
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
EC Number:
252-100-0
MDL number:
Form:
powder
Quality level:
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助


产品名称

酮替芬 富马酸盐,

form

powder

Quality Level

originator

Novartis

SMILES string

OC(=O)\C=C\C(O)=O.CN1CCC(\CC1)=C2/c3ccccc3CC(=O)c4sccc24

InChI

1S/C19H19NOS.C4H4O4/c1-20-9-6-13(7-10-20)18-15-5-3-2-4-14(15)12-17(21)19-16(18)8-11-22-19;5-3(6)1-2-4(7)8/h2-5,8,11H,6-7,9-10,12H2,1H3;1-2H,(H,5,6)(H,7,8)/b;2-1+

InChI key

YNQQEYBLVYAWNX-WLHGVMLRSA-N

Gene Information

General description

富马酸酮替芬盐是一种抗组胺药。

Application

富马酸酮替芬盐已被用于:肥大细胞产物拮抗作用,作为 β-氨基己糖苷酶释放测试的阳性对照,作为肥大细胞稳定剂添加到饮用水中用于治疗怀孕母兽

Biochem/physiol Actions

富马酸酮替芬通过阻断组胺H1受体而在阻止组胺的释放中起关键作用。它会干扰肥大细胞释放组胺、血清素和其他炎症介质。它具有抗过敏活性、消炎作用(包括使肥大细胞稳定)。它已被广泛用于眼部过敏性结膜炎。
H1 组胺受体拮抗剂。

Features and Benefits

该化合物由 Novartis 开发。想要浏览其他由制药公司开发的化合物以及已批准药物/候选药物清单,请单击此处


ppe

dust mask type N95 (US), Eyeshields, Faceshields, Gloves

pictograms

Exclamation mark

signalword

Warning

hcodes

Hazard Classifications

Acute Tox. 4 Oral - Eye Irrit. 2

存储类别

11 - Combustible Solids

wgk

WGK 3



历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库



Jing Wang et al.
Diabetes/metabolism research and reviews, 27(8), 919-924 (2011-11-10)
Mast cells are essential in allergic responses and beyond. White adipose tissue from obese humans contains large numbers of mast cells. Serum mast cell tryptase levels are also significantly higher in obese subjects than in lean subjects, suggesting a role
Katsuya Unno et al.
European journal of pharmacology, 683(1-3), 179-185 (2012-03-28)
First generation H₁ histamine receptor antagonists, such as d-chlorpheniramine (d-CPA) and diphenhydramine, produce drowsiness in humans. They are currently used as over-the-counter sleep aids. However, the mechanisms underlying drowsiness induced by these H₁ histamine receptor antagonists remain obscure because they
A Tieppo et al.
Journal of controlled release : official journal of the Controlled Release Society, 157(3), 391-397 (2011-10-11)
In this paper, we demonstrate the successful in vivo extended release of a small molecular weight therapeutic, ketotifen fumarate (MW=425), from molecularly imprinted, therapeutic contact lenses. This is the first time that a steady, effective concentration of drug is maintained



全球贸易项目编号

货号GTIN
K2628-1G04061833868331
K2628-100MG04061833868324